Search | Clinical Trials Finder

Conditions: Cervical Cancer
Interventions: Pembrolizumab, Paclitaxel, Cisplatin, Carboplatin, Bevacizumab, Placebo to pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 20
States / cities: Anchorage, Alaska • Phoenix, Arizona • Orange, California + 15 more

Conditions: Short Bowel Syndrome
Interventions: HM15912 Active, Placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Cleveland, Ohio

Conditions: Parkinson's Disease
Interventions: Inosine, Placebo; Drug
Lead sponsor: Michael Alan Schwarzschild; Other
Eligibility: 30 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more

Conditions: Parkinson Disease
Interventions: Digital music therapeutic, Active-Control; Device · Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 40 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson's Disease
Interventions: Exercise; Behavioral
Lead sponsor: Radboud University Medical Center; Other
Eligibility: 30 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bullous Pemphigoid
Interventions: QGE031, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 20 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Iowa City, Iowa • Durham, North Carolina

Conditions: PARKINSON DISEASE (Disorder)
Interventions: A metacognitive strategy for cognitive rehabilitation called the Multicontext Approach., Cognitive (Process) Training, MC Approach Booster Session; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non Small Cell Lung Cancer
Interventions: Stereotactic radiation therapy, Durvalumab; Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Parkinson Disease
Interventions: Progressive Resistance Training (PRT), Delayed Exercise Training (DE), Endurance Training (ET); Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes Mellitus
Interventions: Dapagliflozin, Placebo matching Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 12
States / cities: Chula Vista, California • San Diego, California • Torrance, California + 9 more

Conditions: Parkinson Disease, Movement Disorders
Interventions: Deep Brain Stimulation Surgical Procedures as Part of Routine Clinical Care; Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Amblyopia, Strabismus
Interventions: Pediatric Vision Scanner; Device
Lead sponsor: Rebiscan, Inc.; Industry
Eligibility: 2 Years to 6 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Parkinson's Disease, Multiple System Atrophy, Autonomic Failure
Interventions: 13N-Ammonia, 18F-DOPA, 11C-Methylreboxetine (11C-MRB), 18F-Dopamine; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson Disease
Interventions: PD neurofeedback, PD control; Other
Lead sponsor: Yale University; Other
Eligibility: 40 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Alzheimers Disease
Interventions: RO7126209, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 15
States / cities: Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 12 more

Conditions: Thermal Burn
Interventions: PermeaDerm®, Mepilex Ag; Device
Lead sponsor: Stedical Scientific, Inc.; Industry
Eligibility: Up to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years to 70 Years
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Renal Insufficiency
Interventions: LHW090, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Sacituzumab Govitecan, Pembrolizumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 16
States / cities: Mobile, Alabama • Oceanside, California • Clermont, Florida + 12 more

Conditions: Heart Failure
Interventions: THRV-1268, Placebo; Drug
Lead sponsor: Thryv Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
Interventions: RO7204239, RO7204239 Matching Placebo, Tirzepatide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Anniston, Alabama • Spring Valley, California • Clermont, Florida + 16 more

Conditions: CKD Anemia in Stable Dialysis Patients
Interventions: Epoetin Alfa, Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 74
States / cities: Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more

Conditions: Inflammation, Depression Disorder, Mindfulness, Emotional Well-being, Physical Health, Mental Health
Interventions: Mindfulness-based cognitive therapy for perinatal depression, Pregnancy Health Group; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Atherosclerosis
Interventions: Selnoflast, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 24
States / cities: Beverly Hills, California • Irvine, California • Los Angeles, California + 19 more

Search by objective public record fields.

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

Study of Urate Elevation in Parkinson's Disease, Phase 3

Amped-PD: Amplifying Physical Activity Through Music in Parkinson Disease

The ParkCycle Study: Aerobic Exercise in PD

Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

Multicontext Approach for Cognitive Function in Parkinson Disease

Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

Slow Wave Sleep as a Biomarker of Rehabilitation-induced Cognitive Improvement in PD

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

Cognitive Decline Following Deep Brain Stimulation

Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner

Clinical Laboratory Evaluation of Chronic Autonomic Failure

Effect of Mental Imagery Training on Brain Plasticity and Motor Function in Individuals With Parkinson's Disease

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

Evaluation of the Effectiveness of PermeaDerm® (PD) as Compared to Mepilex Ag®

Connecting the Lab to Everyday Life: The Relevance of Executive Dysfunction to Participation and Quality of Life in Parkinson's Disease (PD) Without Dementia

An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

Inflammatory Pathways Modulated by Prenatal Mindfulness: A Route to Improve Maternal Child Emotional Well Being and Whole Person Health

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events